Journal Logo

Articles by T. Vassilakopoulos

COMPARISON OF RITUXIMAB DOSE-ADJUSTED EPOCH (R-DA-EPOCH) WITH RITUXIMAB-CHOP (R-CHOP) CHEMOTHERAPY IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): PF297

Vassilakopoulos, T.; Mellios, Z.; Verigou, E.; More

HemaSphere. 3:100-101, June 2019.

VERY LATE REALAPSES (VLR) ≥5 YEARS AFTER INITIAL TREATMENT WITH CHEMOTHERAPY±RADIOTHERAPY (CT±RT) IN HODGKIN LYMPHOMA (HL): A JOIN STUDY ON TREATMENT STRATEGIES AND PROGNOSTIC FACTORS FOR THE OUTCOME: PF472

Vassilakopoulos, T.; Liaskas, A.; Rizzuto, G.; More

HemaSphere. 3:187-188, June 2019.

THE STAT SIGNALING BIOSIGNATURE OF CD4+ T CELL SUBSETS REFLECT THE IMMUNOGENICITY OF HIGH-RISK MDS AND PREDICT AZACYTIDINE TREATMENT OUTCOME: PF537

Lamprianidou, E.; Kordella, C.; Zoulia, E.; More

HemaSphere. 3:221-222, June 2019.

PET-SCAN FOR RESPONSE ASSESSEMENT AFTER RITUXIMAB-DOSE-ADJUSTED-EPOCH (R-DA-EPOCH) IN PRIMARY MEDIASTINAL LARGE B-CELL LYMPHOMA (PMLBCL): CLINICAL AND PROGNOSTIC SIGNIFICANCE: PS1089

Vassilakopoulos, T.; Chatzidimitriou, C.; Mellios, Z.; More

HemaSphere. 3:494, June 2019.

CLONAL B-CELL LYMPHOCYTOSIS OF MARGINAL ZONE ORIGIN (CBL-MZ): CLINICAL SIGNIFICANCE OF ABSOLUTE CLONAL B CELL COUNTS: PS1258

Kalpadakis, C.; Pangalis, G.; Konstantinou, I.; More

HemaSphere. 3:575, June 2019.